Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symp. case 91% primary Improvement Relative Risk Severe case 93% Ivermectin  Shouman et al.  Prophylaxis  RCT Is prophylaxis with ivermectin beneficial for COVID-19? RCT 304 patients in Egypt (June - July 2020) Fewer symptomatic cases (p=0.001) and lower severe cases (p=0.0022) Shouman et al., J. Clinical and Diagno.., Aug 2020 Favors ivermectin Favors control

Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial

Shouman et al., Journal of Clinical and Diagnostic Research, doi:10.7860/JCDR/2020/46795.0000, NCT04422561
Aug 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
PEP trial for asymptomatic close contacts of COVID-19 patients, 203 ivermectin patients and 101 control patients. 7.4% of contacts developed COVID-19 in the ivermectin group vs. 58.4% in the control group. Efficacy for symptomatic cases and severe cases is very similar. Adjusted results are provided only for symptomatic cases. See also
This is the 2nd of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 4th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of symptomatic case, 91.3% lower, RR 0.09, p < 0.001, treatment 15 of 203 (7.4%), control 59 of 101 (58.4%), NNT 2.0, adjusted per study, inverted to make RR<1 favor treatment, multivariate, primary outcome.
risk of severe case, 92.9% lower, RR 0.07, p = 0.002, treatment 1 of 203 (0.5%), control 7 of 101 (6.9%), NNT 16, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shouman et al., 28 Aug 2020, Randomized Controlled Trial, Egypt, peer-reviewed, 8 authors, study period 1 June, 2020 - 28 July, 2020, dosage 18mg days 1, 3, dose varies depending on weight - 40-60kg: 15mg, 60-80kg: 18mg, >80kg: 24mg, trial NCT04422561 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial
Waheed M Shoumann, Dr Abdelmonem Awad Hegazy, Ramadan M Nafae, Moustafa I Ragab, Saad R Samra, Dalia Anas Ibrahim, Tarek H Al-Mahrouky, Ashraf E Sileem
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, doi:10.7860/jcdr/2021/46795.14529
Introduction: The rate of secondary attacks of SARS-COV-2 is high among household close contacts. Social distancing, isolation and infection control measures are important for preventing exposure to infection, but insufficient. Aim: The study aimed to evaluate possible role of oral ivermectin as a chemoprophylaxis in asymptomatic family close contacts with COVID-19 patients. Materials and Methods: A prospective interventional randomised open label-controlled study was conducted (registered at; NCT04422561) during June and July 2020. Two arms were designed according to use of ivermectin. In ivermectin arm, contacts received ivermectin according to Body Weight (BW) on day of the diagnosis of their index case. The non-intervention group received no treatment. Both groups were followed-up for two weeks for development of symptoms suggestive of COVID-19. Results: Ivermectin group included 203 contacts (to 52 index cases) aged 39.75±14.94 years; 52.2% were males. Nonintervention group included 101 contacts (to a total of 24 index cases) aged 37.69±16.96 years, 49.5% were males. Fifteen contacts (7.4%) developed COVID-19 in the ivermectin arm compared to 59 (58.4%) in the non-intervention arm (p<0.001). The protection rate for ivermectin was more prominent in contacts aged less than 60-year-old (6.2% infected compared to 58.7% if no treatment). Ivermectin in the protection against SARS-CoV-2 infection had an OR of 12.533 and 11.445 (compared to nontreatment) in both univariate and multivariate models, respectively. Side effects of ivermectin were reported in 5.4%; they were mild. Conclusion: Ivermectin is suggested to be a promising, effective and safe chemoprophylactic drug in management of COVID-19.
Am, Liébana, Martínez, None
Azeem, Ashraf, Rasheed, Anjum, Hameed, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication, doi:10.1016/j.antiviral.2013.10.004
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., None, Int J Rheum Dis, doi:10.1111/1756-185X.13842
Caly, Druce, Catton, Jans, Wagstaff, situation?, doi:10.7189/jogh.10.010368
Guzzo, Furtek, Porras, Chen, Tipping et al., None
Hegazy, Hegazy, COVID-19
Heidary, Gharebaghi, Ivermectin: A systematic review from antiviral effects
Ketkar, Yang, Wormser, Wang, Lack of efficacy of ivermectin for
Li, Zhang, Lu, Chang, Cao et al., The characteristics of household, J Infect, doi:10.1016/j.jinf.2020.03.040
Liu, Yan, Wan, Xiang, Le et al., from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2020.1775118
Mastrangelo, Pezzullo, Burghgraeve, Kaptein, Pastorino et al., None
Mitjà, Clotet, Use of antiviral drugs to reduce COVID-19 transmission, Lancet
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment
Morris-Jones, Oral ivermectin for infants and children under 15 kg appears to
Petersen, Koopmans, Go, Hamer, Petrosillo et al., None
Randolph, Barreiro, Herd immunity: Understanding COVID-19, doi:10.1056/NEJMoa2016638
Shah, Das, Jain, Misra, Negi, A systematic review of the prophylactic
Therapeutics ; Medhat, Afro-Egypt, J Infect Endem Dis, doi:10.21608/AEJI.2020.93432
Vega, Vieitez, The pharmacokinetics and interactions of ivermectin in humans-A mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
Vora, Arora, Behera, Tripathy, White paper on Ivermectin as a potential [11] therapy for COVID-19, Indian J Tuberc, doi:10.1016/j.ijtb.2020.07.031
Wagstaff, None, Sci Rep
Wang, Ma, Zheng, Wu, Zhang, Household transmission of SARS, doi:10.1016/j.immuni.2020.04.012
Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop